XT 150
Alternative Names: IL-10 transgene plasmid DNA; XT 101; XT-101-R; XT-150Latest Information Update: 28 Mar 2026
At a glance
- Originator Xalud Therapeutics
- Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Gene therapies; Non-opioid analgesics; Skin disorder therapies
- Mechanism of Action Gene transference; Interleukin 10 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Musculoskeletal pain
- Research Unspecified
- No development reported Amyotrophic lateral sclerosis; Eye disorders; Gastrointestinal disorders; Multiple sclerosis; Neuropathic pain; Skin disorders
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
- 28 Mar 2026 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)
- 28 Mar 2026 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (Parenteral)